BCR-ABL BREAKPOINT AND PROGNOSIS IN CHRONIC MYELOID LEUKEMIA

To the Editor:
The review article by Mills et all was timely and welcome. They raised a number of points that are relevant to the study of the prognosis of chronic myeloid leukemia (CML). We would like to add three points. First, the number of patients in any series was too small to detect a difference between two groups, unless that difference was very great. Second, the assessment of chronic phase duration is not reliable, as the majority of patients progress from chronic to blastic phase (or from chronic phase to death without a true blastic phase) through an accelerated phase that is difficult to date. Survival length is much more exact and reliable than chronic phase duration. Third, the review did not or could not take into consideration the relationship between breakpoint site and other previously established prognostic features and formulation^.^^^ To make a simple example, since it was established that spleen size and peripheral blood blast cell proportion are inversely related to survival length, it cannot be sufficient to report that one breakpoint site or the other is or is not related to survival length. It is necessary to know also if it is related or not, eg, to spleen size and blast cells. If molecular lesions would correlate with prognosis and with prognostic features, this would provide the latter with a molecular basis that would be worth investigating. But this would not allow substitution of a simple and cheap prognostic factor or system with a more sophisticated and expensive one. In contrast, if molecular lesions would correlate with prognosis but not with previously established prognostic features, molecular data should be quickly incorporated into appropriate prognostic formulations.
The final message of Mills et al, calling for prospective studies in this area, was pursued by the Italian CML Study Group since 1989, and we are currently investigating the meaning of the breakpoint in an unbiased and unselected cohort of 236 Ph+ CML patients who 
RESPONSE
The points raised by Baccarani et a1 make an important contribution to the controversy concerning M-bcr breakpoint location and prognosis. Our review' attempted to identify similarities and differences in those reports that had been published at that time to try to determine why different laboratories came to disparate conclusions. In this respect we could only compare data that had been included in these reports, although an ideal situation would have involved a comparison of all clinical and molecular data. In no way did we wish to suggest a direct substitution of breakpoint site determination for other prognostic features, but rather the addition of these data to give a more accurate prognosis. Nevertheless, some of the studies reviewed did suggest that breakpoint location could be an important factor (although not necessarily the only one) in determining disease duration. If the molecular breakpoint is eventually shown to be a prognostic indicator, either alone or together with other features of the the disease, this must suggest that it is important enough to warrant studying.
We agree that estimating chronic phase duration i s not easy, but this is not so much because of difficulties in assessing the time of onset of blast crisis in the vast majority of cases because "accelerated phase" is relatively short in most patients. Much more difficult is assessing the time of onset of chronic phase, a point we made in our review.' Because this has the same effect on the estimate of survival time as on that of the chronic phase duration, the former is no more accurate or reliable. Indeed, it could be less so because the frequency of recurrence of blast crisis can vary enormously, depending to some extent on the therapy used in blast crisis.
It would certainly be better to include correlations of breakpoint location with other factors, but this information is not generally available. It is clear from our review' that a variety of factors influence the length of chronic phase, hence our call for a detailed prospective study. The Italian prospective study of 236 patients is a step in the right direction. However, if factors related to geography, socioeconomic status, population homogeneity, and environment are important, similar and larger studies from other widely distributed centers are required. It would help if, in addition, a multicenter database of all data relating to CML patients were established; in this way some clues as to the best prognostic indicators and possibly the causes of progression might be revealed. 
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